ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 136,68
-0,95%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Actualités

ARQT Arcutis Biotherapeutics Inc

8,31
-0,28 (-3,26%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Arcutis Biotherapeutics Inc ARQT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,28 -3,26% 8,31 01:46:45
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
8,59 8,36 8,85 8,47 8,59
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
10/4/202414:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05/4/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/4/202413:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/3/202413:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/3/202413:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10/3/202421:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09/3/202422:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
06/3/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04/3/202423:47EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:42EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:40EDGAR2Form 144 - Report of proposed sale of securities
04/3/202422:10EDGAR2Form 8-K - Current report
04/3/202422:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/3/202414:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
01/3/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202423:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/2/202405:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28/2/202422:54EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202422:10EDGAR2Form 8-K - Current report
28/2/202422:10GLOBEArcutis Announces Proposed Public Offering
28/2/202422:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27/2/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202413:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:44EDGAR2Form 8-K - Current report
27/2/202411:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16/2/202414:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
16/2/202400:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:20EDGAR2Form 8-K - Current report
15/2/202422:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
13/2/202415:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08/2/202422:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
31/1/202423:22EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202414:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
29/1/202414:00GLOBEJournal of the American Academy of Dermatology Publishes..
24/1/202422:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
22/1/202414:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
17/1/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/1/202410:00GLOBEMajority of Individuals with Atopic Dermatitis Improved with..

Dernières Valeurs Consultées

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés